共 50 条
- [41] Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2022, 23 (06): : 739 - 747Wang, JieZhou, CaicunYao, WenxiuWang, QimingMin, XuhongChen, GongyanXu, XingxiangLi, XingyaXu, FeiFang, YongYang, RunxiangYu, GuohuaGong, YoulingZhao, JunFan, YunLiu, QuanCao, LejieYao, YuLiu, YunpengLi, XiaolingWu, JingxunHe, ZhiyongLu, KaihuaJiang, LiyanHu, ChengpingZhao, WenhuaZhang, BenShi, WeiZhang, XiaojingCheng, Ying
- [42] CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Spigel, David R.Zielinski, ChristophMaier, Sabinede Pril, VeerleFairchild, Justin P.Cuillerot, Jean-MarieReck, Martin
- [43] A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerSIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)Chen, ZhiweiChen, JianhuaHuang, DingzhiZhang, WeiWu, LinYi, TienanWang, QimingHan, LiangTan, LipingLi, YinyinZhang, ZhihongLi, NaLi, JieZhang, TongmeiHu, YingSun, HongmeiWu, YouhuaHe, ZhiyongYang, RunxiangCheng, PengLi, XingyaShi, JianhuaYu, GuohuaMa, DaiyuanLi, Benjamin XiaoyiDai, XiangrongWong, MichaelLi, YujieYu, XiaohuiLu, ShunSocazolimab Study Grp, Benjamin Xiaoyi
- [44] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +Chesney, Jason A.Ribas, AntoniLong, Georgina, VKirkwood, John M.Dummer, ReinhardPuzanov, IgorHoeller, ChristophGajewski, Thomas F.Gutzmer, RalfRutkowski, PiotrDemidov, LevArenberger, PetrShin, Sang JoonFerrucci, Pier FrancescoHaydon, AndrewHyngstrom, Johnvan Thienen, Johannes, VHaferkamp, SebastianGuilera, Josep MalvehyRapoport, Bernardo LeonVanderWalde, AriDiede, Scott J.Anderson, James R.Treichel, SherylChan, Edward L.Bhatta, SumitaGansert, JenniferHodi, Frank StephenGogas, Helen
- [45] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547Reinmuth, N.DeMarinis, F.Leighl, N.Sadow, S.Davey, K.Ozguroglu, M.
- [46] SALUTE: a placebo-controlled, double-blind, multicenter, randomized, phase II study of bevacizumab in previously untreated extensive-stage small cell lung cancer (SCLC)JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S398 - S398Spigel, David R.Townley, Peter M.Waterhouse, David M.Fang LiangAdiguzel, IbrahimHuang, Jane E.Scappaticci, Frank A.Socinski, Mark A.
- [47] Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trialLANCET ONCOLOGY, 2023, 24 (04): : 392 - 402Monk, Bradley J.Tewari, Krishnansu S.Dubot, CoralineCaceres, M. ValeriaHasegawa, KoseiShapira-Frommer, RonnieSalman, PamelaYanez, EduardoGuemues, MahmutMendoza, Mivael Olivera Hurtado deSamouelian, VanessaCastonguay, VincentArkhipov, AlexanderTekin, CumhurLi, KanNguyen, Allison MartinMonberg, Matthew J.Colombo, NicolettaLorusso, Domenica
- [48] Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) : 193 - +Finn, Richard S.Ryoo, Baek-YeolMerle, PhilippeKudo, MasatoshiBouattour, MohamedLim, Ho YeongBreder, ValeriyEdeline, JulienChao, YeeOgasawara, SadahisaYau, ThomasGarrido, MarceloChan, Stephen L.Knox, JenniferDaniele, BrunoEbbinghaus, Scot W.Chen, ErluoSiegel, Abby B.Zhu, Andrew X.Cheng, Ann-Lii
- [49] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Petrylak, Daniel P.Ratta, RaffaeleMatsubara, NobuakiKorbenfeld, Ernesto PabloGafanov, RustemMourey, LoicTodenhofer, TilmanGurney, HowardKramer, GeroBergman, Andre M.Zalewski, PawelDe Santis, MariaArmstrong, Andrew J.Gerritsen, Winald R.Pachynski, Russell KentByun, Seok-SooLi, Xin TongSchloss, CharlesPoehlein, Christian HeinrichFizazi, Karim
- [50] KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaAMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (05): : 476 - 484Hauser, Robert A.Factor, Stewart A.Marder, Stephen R.Knesevich, Mary AnnRamirez, Paul M.Jimenez, RolandBurke, JoshuaLiang, Grace S.O'Brien, Christopher F.